Read our latest updates & insights

Prestige releases details of upcoming Phase III clinical trials of biosimilar bevacizumab candidate.

Alteogen announces Phase I clinical trials of biosimilar aflibercept candidate will begin this month.

Lupin announces plans to file applications for biosimilar etanercept in the US market by the fourth quarter of FY20.

Samsung Bioepis releases results of Benepali® psoriasis study, announcing results demonstrate the product’s effectiveness and safety in a real-world setting. The study was conducted by the British Association of Dermatologists, Biologics and Immunomodulators Registry ...

The Institute for Clinical and Economic Review releases its report on Unsupported Price Increases, highlighting AbbVie’s Humira® as one of the products with price increases which are unsupported by new clinical evidence. 

The Institute for Clinical and Economic Review releases its report on Unsupported Price Increases, highlighting Roche’s Rituxan® as one of the products with price increases which are unsupported by new clinical evidence. 

Celltrion and Juno announce Australian co-marketing partnership agreement for Herzuma® (trastuzumab) and Truxima® (rituximab). Under the agreement, Celltrion will hold the marketing authorisation and will be responsible for distribution, and Juno will provide sales promotio...

FDA issues a complete response letter for Tanvex’s proposed filgrastim biosimilar. Tanvex has announced that the FDA did not request additional clinical data or express concern related to product safety, but that certain items needed to be addressed before the applica...

Biocon announces purchase of 60,000 square foot R&D site from Pfizer. The site in Chennai, India will house 250 scientists and is expected to be operational in a few months.